CA3019536A1 - Live, attenuated alphavirus constructs and methods and uses thereof - Google Patents

Live, attenuated alphavirus constructs and methods and uses thereof Download PDF

Info

Publication number
CA3019536A1
CA3019536A1 CA3019536A CA3019536A CA3019536A1 CA 3019536 A1 CA3019536 A1 CA 3019536A1 CA 3019536 A CA3019536 A CA 3019536A CA 3019536 A CA3019536 A CA 3019536A CA 3019536 A1 CA3019536 A1 CA 3019536A1
Authority
CA
Canada
Prior art keywords
ires
virus
alphavirus
attenuated
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3019536A
Other languages
English (en)
French (fr)
Inventor
Jill Ann LIVENGOOD
Timothy Duane Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CA3019536A1 publication Critical patent/CA3019536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3019536A 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof Abandoned CA3019536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
US62/316,264 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
CA3019536A1 true CA3019536A1 (en) 2017-10-05

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019536A Abandoned CA3019536A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Country Status (17)

Country Link
US (1) US20190106682A1 (enExample)
EP (1) EP3436062A1 (enExample)
JP (1) JP2019509750A (enExample)
KR (1) KR20180135913A (enExample)
CN (1) CN109195625A (enExample)
AU (1) AU2017241669A1 (enExample)
BR (1) BR112018069079A2 (enExample)
CA (1) CA3019536A1 (enExample)
CO (1) CO2018010359A2 (enExample)
CR (1) CR20180457A (enExample)
DO (1) DOP2018000209A (enExample)
EC (1) ECSP18081582A (enExample)
MX (1) MX2018011839A (enExample)
PE (1) PE20190178A1 (enExample)
PH (1) PH12018502120A1 (enExample)
SG (1) SG11201808479VA (enExample)
WO (1) WO2017172698A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020024292A2 (pt) * 2018-06-06 2021-03-02 Massachusetts Institute Of Technology rna circular para translação em células eucarióticas
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技（深圳）有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
KR101668849B1 (ko) * 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Also Published As

Publication number Publication date
KR20180135913A (ko) 2018-12-21
ECSP18081582A (es) 2019-02-28
SG11201808479VA (en) 2018-10-30
CO2018010359A2 (es) 2018-12-14
AU2017241669A1 (en) 2018-11-22
CN109195625A (zh) 2019-01-11
EP3436062A1 (en) 2019-02-06
PH12018502120A1 (en) 2019-07-15
DOP2018000209A (es) 2019-01-31
CR20180457A (es) 2019-04-09
US20190106682A1 (en) 2019-04-11
PE20190178A1 (es) 2019-02-01
BR112018069079A2 (pt) 2019-01-29
JP2019509750A (ja) 2019-04-11
MX2018011839A (es) 2019-05-23
WO2017172698A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
US20190106682A1 (en) Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
US10533186B2 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US20200270584A1 (en) Method for rapid generation of an attenuated rna virus
US8343506B2 (en) Chimeric chikungunya virus and uses thereof
US20200113984A1 (en) Alphavirus Replicon Particles Expressing TRP2
WO2018129160A1 (en) Live attenuated flavivirus vaccines and methods of using and making same
US20140065178A1 (en) Methods and Compositions for Pseudoinfectious Alphaviruses
HK40003300A (en) Live, attenuated alphavirus constructs and methods and uses thereof
AU2018229512B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
Tulloch et al. Problems in FMD eradication: a way forward?
AU2014265084B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
Monath Recombinant, chimeric, live, attenuated vaccines against flaviviruses and alphaviruses
WO2007002793A2 (en) Chimeric sindbis-eastern equine encephalitis virus and uses thereof
HK1230647A1 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220929

FZDE Discontinued

Effective date: 20220929